AG
FHTX icon

Algert Global’s Foghorn Therapeutics FHTX Stock Holding History

Algert Global’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67K Hold
13,928
– – ﹤0.01% 1123
2025
Q4 		$75K Buy
+13,928
New +$63.1K ﹤0.01% 1104

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Algert Global's FHTX Position: Q1 2026 in Review

Algert Global held its Foghorn Therapeutics (FHTX) position steady in Q1 2026 at 13,928 shares worth $67K. The position accounts for ﹤0.01% of the portfolio, ranked #1123.

Algert Global first reported a position in FHTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $75K in Q4 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Algert Global held 13,928 shares of Foghorn Therapeutics worth $67K as of Q1 2026.
  • Algert Global left its Foghorn Therapeutics share count unchanged in Q1 2026.
  • Foghorn Therapeutics made up ﹤0.01% of Algert Global's portfolio in Q1 2026, its #1123 holding.
  • Algert Global first reported a position in Foghorn Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Algert Global's Foghorn Therapeutics position peaked at $75K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.